Literature DB >> 8335516

Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man.

W A Craig1.   

Abstract

Persistent suppression of bacterial growth, called the post-antibiotic effect (PAE), has been studied in six different animal infection models. Prolonged in-vivo PAEs are observed for all antimicrobials with staphylococci and for imipenem and inhibitors of protein and nucleic acid synthesis with streptococci and Gram-negative bacilli. Penicillins and cephalosporins produce short or no in-vivo PAEs with these latter organisms. The presence of neutrophils prolongs the in-vivo PAEs found with aminoglycosides and quinolones. Simulation of human pharmacokinetics also enhances the duration of in-vivo PAE for aminoglycosides. In-vivo PAEs tend to be longer than those observed in vitro. The in-vitro PAE for penicillin with streptococci has been observed in vivo in only one of four experimental infection models. The presence of a prolonged in-vivo PAE can allow wider dosing intervals. The primary clinical application of the in-vivo PAE has been with once-daily dosing of aminoglycosides.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335516     DOI: 10.1093/jac/31.suppl_d.149

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  44 in total

Review 1.  Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.

Authors:  R C Li; M Zhu; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

2.  Postantibiotic suppression of growth of erythromycin A-susceptible and -resistant gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004.

Authors:  W J Munckhof; G Borlace; J D Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 3.  Aminoglycosides: activity and resistance.

Authors:  M P Mingeot-Leclercq; Y Glupczynski; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

4.  Pharmacodynamics and alternative antimicrobial dosing regimens.

Authors:  J Conly; S Shafran
Journal:  Can J Infect Dis       Date:  1995-01

5.  Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments.

Authors:  Bruce R Levin; Klas I Udekwu
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

6.  Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection.

Authors:  Irma A J M Bakker-Woudenberg; Marian T ten Kate; Wil H F Goessens; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

7.  Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus.

Authors:  Jun Taek Oh; Cara Cassino; Raymond Schuch
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

8.  Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.

Authors:  Vanessa E Rees; Jürgen B Bulitta; Antonio Oliver; Brian T Tsuji; Craig R Rayner; Roger L Nation; Cornelia B Landersdorfer
Journal:  J Antimicrob Chemother       Date:  2016-08-11       Impact factor: 5.790

9.  Postantibiotic effect of ceftaroline against gram-positive organisms.

Authors:  G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-10       Impact factor: 5.191

10.  Initial concentration-time profile of gentamicin determines efficacy against Enterobacter cloacae ATCC 13047.

Authors:  C R Rayner; L L Ioannides-Demos; J A Brien; L L Liolios; W J Spicer
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.